Myla P. Lai-Goldman, MD
Managing Partner, Personalized Science LLC
In 2009, Dr. Lai-Goldman founded and became the managing partner of Personalized Science, LLC, a consulting company whose mission is to assist its customers achieve successful adoption of innovative diagnostics with actionable results for patient’s unmet medical needs.
In 2011, Dr Lai-Goldman founded and became CEO of GeneCentric Diagnostics, Inc., focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions.
Also, in 2011, Dr. Lai-Goldman became a Venture Partner with Hatteras Venture Partners, Inc, a venture capital firmed based in Research Triangle Park, NC with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine.
Until her retirement on December 31, 2008, Myla P. Lai-Goldman, M.D. was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp's National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. Dr. Lai-Goldman served as a member of LabCorp's Executive Committee from April 1998 until her retirement from the company.
From 1998 until April 2008, Dr. Lai-Goldman also served as Chief Scientific Officer of the company, where she was responsible for R & D. Until 2006, she managed the operations of the Company’s Center for Molecular Biology and Pathology in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; and ViroMed Laboratories, Inc. in Minneapolis, MN. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Dr. Lai-Goldman joined the Company in 1990.
Dr. Lai-Goldman earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke’s Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.